BELLUS Health (TSE:BLU) Share Price Passes Below 50 Day Moving Average of $12.23

BELLUS Health Inc. (TSE:BLU – Get Rating) shares crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of C$12.23 and traded as low as C$9.85. BELLUS Health shares last traded at C$9.99, with a volume of 108,705 shares traded.

Analysts Set New Price Targets

Separately, Evercore ISI reissued a “buy” rating and set a C$24.00 price target on shares of BELLUS Health in a research report on Tuesday, November 15th.

BELLUS Health Stock Performance

The company has a debt-to-equity ratio of 0.15, a quick ratio of 16.40 and a current ratio of 16.96. The firm’s 50 day simple moving average is C$12.23 and its 200-day simple moving average is C$13.14. The company has a market cap of C$1.26 billion and a price-to-earnings ratio of -9.51.

BELLUS Health (TSE:BLU – Get Rating) last announced its quarterly earnings results on Monday, November 14th. The company reported C($0.26) earnings per share for the quarter, missing the consensus estimate of C($0.24) by C($0.02). The firm had revenue of C$0.01 million for the quarter, compared to analysts’ expectations of C$0.01 million. On average, sell-side analysts predict that BELLUS Health Inc. will post -0.87 EPS for the current year.

Insider Activity

In other news, Director Joseph Rus sold 35,643 shares of the business’s stock in a transaction dated Friday, November 18th. The shares were sold at an average price of C$12.14, for a total transaction of C$432,559.88. In other news, Director Joseph Rus sold 35,643 shares of the business’s stock in a transaction dated Friday, November 18th. The shares were sold at an average price of C$12.14, for a total transaction of C$432,559.88. Also, Director Pierre Larochelle sold 35,667 shares of the business’s stock in a transaction dated Wednesday, November 30th. The shares were sold at an average price of C$12.59, for a total transaction of C$448,976.20. Following the transaction, the director now directly owns 131,389 shares in the company, valued at approximately C$1,653,924.73.

About BELLUS Health

(Get Rating)

BELLUS Health Inc, a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.